Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Aultman Health Foundation
mi
from
Canton, OH
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Aultman Health Foundation
mi
from
Canton, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Jewish Hospital
mi
from
Cincinnati, OH
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Jewish Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic Cancer Center Independence
mi
from
Independence, OH
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic Cancer Center Independence
mi
from
Independence, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Rita's Medical Center
mi
from
Lima, OH
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Rita's Medical Center
mi
from
Lima, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic Wooster Family Health and Surgery Center
mi
from
Wooster, OH
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic Wooster Family Health and Surgery Center
mi
from
Wooster, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Cancer Care Associates
mi
from
Oklahoma City, OK
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Cancer Care Associates
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Natalie Warren Bryant Cancer Center at Saint Francis
mi
from
Tulsa, OK
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Natalie Warren Bryant Cancer Center at Saint Francis
mi
from
Tulsa, OK
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Lehigh Valley Hospital-Cedar Crest
mi
from
Allentown, PA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Lehigh Valley Hospital-Cedar Crest
mi
from
Allentown, PA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Geisinger Wyoming Valley/Henry Cancer Center
mi
from
Wilkes-Barre, PA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Geisinger Wyoming Valley/Henry Cancer Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
WellSpan Health-York Hospital
mi
from
York, PA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
WellSpan Health-York Hospital
mi
from
York, PA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
AnMedical Health Hospital
mi
from
Anderson, SC
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
AnMedical Health Hospital
mi
from
Anderson, SC
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
McLeod Regional Medical Center
mi
from
Florence, SC
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
McLeod Regional Medical Center
mi
from
Florence, SC
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Spartanburg Medical Center
mi
from
Spartanburg, SC
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Spartanburg Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Avera Cancer Institute
mi
from
Sioux Falls, SD
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Avera McKennan Hospital and University Health Center
mi
from
Sioux Falls, SD
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Avera McKennan Hospital and University Health Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Baylor Saint Luke's Medical Center
mi
from
Houston, TX
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Baylor Saint Luke's Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Ben Taub General Hospital
mi
from
Houston, TX
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Ben Taub General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Methodist Hospital System
mi
from
Houston, TX
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Methodist Hospital System
mi
from
Houston, TX
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Wilford Hall Medical Center
mi
from
Lackland Air Force Base, TX
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Wilford Hall Medical Center
mi
from
Lackland Air Force Base, TX
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Sandra L. Maxwell Cancer Center
mi
from
Cedar City, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Sandra L. Maxwell Cancer Center
mi
from
Cedar City, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Logan Regional Hospital
mi
from
Logan, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Logan Regional Hospital
mi
from
Logan, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Intermountain Medical Center
mi
from
Murray, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
McKay-Dee Hospital Center
mi
from
Ogden, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
McKay-Dee Hospital Center
mi
from
Ogden, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Utah Valley Regional Medical Center
mi
from
Provo, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Utah Valley Regional Medical Center
mi
from
Provo, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Dixie Medical Center Regional Cancer Center
mi
from
Saint George, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Dixie Medical Center Regional Cancer Center
mi
from
Saint George, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Intermountain Health Care
mi
from
Salt Lake City, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Intermountain Health Care
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Utah Cancer Specialists-Salt Lake City
mi
from
Salt Lake City, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Utah Cancer Specialists-Salt Lake City
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
LDS Hospital
mi
from
Salt Lake City, UT
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Kaiser Permanente Washington
mi
from
Seattle, WA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Kaiser Permanente Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
PeaceHealth United General Medical Center
mi
from
Sedro-Woolley, WA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
PeaceHealth United General Medical Center
mi
from
Sedro-Woolley, WA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Clinic - Chippewa Center
mi
from
Chippewa Falls, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Clinic - Chippewa Center
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Clinic Cancer Center at Sacred Heart
mi
from
Eau Claire, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Clinic Cancer Center at Sacred Heart
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Clinic
mi
from
Marshfield, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Medical Center
mi
from
Marshfield, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Medical Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Ascension Saint Mary's Hospital
mi
from
Rhinelander, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Ascension Saint Mary's Hospital
mi
from
Rhinelander, WI
Click here to add this to my saved trials